Kheiri Babikir, Zayed Yazan, Barbarawi Mahmoud, Osman Mohammed, Chahine Adam, Ahmed Sahar, Bachuwa Ghassan, Hassan Mustafa, Alkhouli Mohamad, Feldman Ted, Bhatt Deepak L
Department of Internal Medicine, Hurley Medical Center/Michigan State University, Flint, MI, USA.
Division of Cardiology, West Virginia University School of Medicine, Morgantown, WV, USA.
Cardiovasc Revasc Med. 2020 Feb;21(2):155-163. doi: 10.1016/j.carrev.2019.04.008. Epub 2019 Apr 17.
Mitral regurgitation (MR) in heart failure (HF) notoriously carries a poor prognosis. While there are multiple interventional options for treatment, the optimal intervention remains controversial. Therefore, we aimed to evaluate the efficacy and safety of surgery, medical therapy, and transcatheter intervention in secondary MR.
A systematic database search was performed to identify all randomized controlled trials (RCTs) that evaluate various interventions for secondary MR. We performed a Bayesian network meta-analysis to calculate odd ratios (ORs) and 95% credible intervals (CIs). The primary endpoint was all-cause mortality. Secondary endpoints were moderate-severe MR, HF-hospitalizations, and freedom from severe HF symptoms.
We identified 12 RCTs (2316 total patients; age 67.6 ± 11; 63% males, and 74% with ischemic cardiomyopathy). There was a significant reduction of mortality at 24-months with transcatheter leaflet repair compared with medical therapy (OR = 0.57; 95% CI = 0.34-0.96). However, there were no significant differences among the competing treatments in all-cause mortality at the earlier time points of 30-days or 12-months (P > 0.05). Recurrent moderate-severe MR was significantly less with valvular interventions compared with medical therapy (P < 0.05), but there were no differences in the rates of HF-hospitalizations or persistent severe HF symptoms between the competing interventions (P > 0.05).
Among patients with HF and secondary MR, transcatheter leaflet repair was associated with significantly reduced 24-month mortality compared with medical therapy. Valvular interventions were associated with lower rates of recurrent moderate-severe MR, but non-significant improvements in clinical outcomes. Further long-term studies are needed to identify the best route of intervention for secondary MR.
心力衰竭(HF)合并二尖瓣反流(MR)的预后 notoriously 较差。虽然有多种介入治疗选择,但最佳干预措施仍存在争议。因此,我们旨在评估手术、药物治疗和经导管介入治疗继发性 MR 的疗效和安全性。
进行系统的数据库检索,以识别所有评估继发性 MR 各种干预措施的随机对照试验(RCT)。我们进行了贝叶斯网络荟萃分析,以计算比值比(OR)和 95%可信区间(CI)。主要终点是全因死亡率。次要终点是中重度 MR、HF 住院以及无严重 HF 症状。
我们识别出 12 项 RCT(共 2316 例患者;年龄 67.6±11;63%为男性,74%患有缺血性心肌病)。与药物治疗相比,经导管瓣叶修复在 24 个月时死亡率显著降低(OR = 0.57;95%CI = 0.34 - 0.96)。然而,在 30 天或 12 个月的早期时间点,各竞争治疗在全因死亡率方面无显著差异(P > 0.05)。与药物治疗相比,瓣膜介入治疗后复发性中重度 MR 显著减少(P < 0.05),但各竞争干预措施在 HF 住院率或持续性严重 HF 症状发生率方面无差异(P > 0.05)。
在 HF 合并继发性 MR 的患者中,与药物治疗相比,经导管瓣叶修复与 24 个月死亡率显著降低相关。瓣膜介入治疗与复发性中重度 MR 发生率较低相关,但临床结局改善不显著。需要进一步进行长期研究以确定继发性 MR 的最佳干预途径。